Anti-Müllerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia.

[1]  M. Hickey,et al.  What is the "ovarian reserve"? , 2015, Fertility and sterility.

[2]  W. Wallace.  Oncofertility and preservation of reproductive capacity in children and young adults , 2011, Cancer.

[3]  A. Iwase,et al.  The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. , 2011, Human reproduction.

[4]  A. Iwase,et al.  Serum anti-Müllerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. , 2010, Fertility and sterility.

[5]  L. Schapira,et al.  Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. , 2010, Fertility and sterility.

[6]  Anjana S. Chauhan,et al.  High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: thirteen years of experience. , 2010, The Journal of reproductive medicine.

[7]  A. Juul,et al.  Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. , 2010, Fertility and sterility.

[8]  M. El-ashry,et al.  Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. , 2009, Fertility and sterility.

[9]  J. Visser,et al.  Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. , 2008, Human reproduction.

[10]  J. García-Velasco,et al.  Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. , 2008, Fertility and sterility.

[11]  R. Berkowitz,et al.  Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. , 2008, The Journal of reproductive medicine.

[12]  E. Winer,et al.  Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer , 2008 .

[13]  P. Sonneveld,et al.  Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. , 2008, Human reproduction.

[14]  C. Lok,et al.  Pregnancy after EMA/CO for gestational trophoblastic disease: a report from The Netherlands , 2003, BJOG : an international journal of obstetrics and gynaecology.

[15]  E. Kohorn.  Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. , 2002, The Journal of reproductive medicine.

[16]  B. Fauser,et al.  Antimüllerian hormone serum levels: a putative marker for ovarian aging. , 2002, Fertility and sterility.

[17]  P. Lorigan,et al.  Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease , 2000, British Journal of Cancer.

[18]  S. Shalet,et al.  Gonadal damage from chemotherapy and radiotherapy. , 1998, Endocrinology and metabolism clinics of North America.

[19]  G J S Rustin,et al.  The management of high‐risk gestational trophoblastic tumours (GTT) , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  P. Donahoe,et al.  Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. , 1996, The Journal of clinical endocrinology and metabolism.